Q&A with Open Orphan (ORPH) CCO Maurice Treacy
Mr. Treacy said: “It’s really important that we bring them on board because they’re a combination of pharma companies, biotech, large and small, and they’re all pretty much in the orphan space so they know the challenges we have the genetics and unravelling the genetics of rare disease”.
Commenting on the benefits of platform for companies, he said: “This research tool can really help them have a complete spectrum of products in pre-clinical and clinical evaluation”
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.